These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17322637)

  • 1. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Kuroda T; Masaki M; Sugiyama S; Okamoto K; Hirota H; Fujio Y; Hori M; Yamauchi-Takihara K
    Circ J; 2007 Mar; 71(3):367-9. PubMed ID: 17322637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
    J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
    Galiè N; Hinderliter AL; Torbicki A; Fourme T; Simonneau G; Pulido T; Espinola-Zavaleta N; Rocchi G; Manes A; Frantz R; Kurzyna M; Nagueh SF; Barst R; Channick R; Dujardin K; Kronenberg A; Leconte I; Rainisio M; Rubin L
    J Am Coll Cardiol; 2003 Apr; 41(8):1380-6. PubMed ID: 12706935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in exercise capacity and cardiac performance in a series of patients with Eisenmenger's syndrome transitioned from selective to dual endothelin receptor antagonist.
    Kopeć G; Tyrka A; Miszalski-Jamka T; Mikołajczyk T; Waligóra M; Guzik T; Podolec P
    Heart Lung Circ; 2012 Nov; 21(11):671-8. PubMed ID: 22819097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hemodynamic effects of single oral dose of bosentan in patients with pulmonary arterial hypertension related to congenital heart disease.
    Ajami G; Ahmadipour M; Amoozgar H; Bourzoee M; Cheriki S; Shakiba AM; Edraki MR
    Congenit Heart Dis; 2014; 9(4):343-8. PubMed ID: 25247216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
    Oldfield V; Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.
    Penn H; Quillinan N; Khan K; Chakravarty K; Ong VH; Burns A; Denton CP
    QJM; 2013 Sep; 106(9):839-48. PubMed ID: 23696678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
    Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
    Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the pulmonary arterial response to endothelin-1 and bosentan in neonatal pigs.
    Domkowski PW; Cockerham JT; Kot PA; Myers JL; Hopkins RA
    Ann Thorac Surg; 2000 Nov; 70(5):1522-30. PubMed ID: 11093481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans.
    Pham I; Wuerzner G; Richalet JP; Peyrard S; Azizi M
    Eur J Clin Invest; 2010 Mar; 40(3):195-202. PubMed ID: 20415698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.
    Vizza CD; Letizia C; Badagliacca R; Poscia R; Pezzuto B; Gambardella C; Nona A; Papa S; Marcon S; Mancone M; Iacoboni C; Riccieri V; Volterrani M; Fedele F
    Int J Cardiol; 2013 Jul; 167(1):220-4. PubMed ID: 22265324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan: a novel agent for the treatment of pulmonary arterial hypertension.
    O'Callaghan D; Gaine SP
    Int J Clin Pract; 2004 Jan; 58(1):69-73. PubMed ID: 14994973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.